A-dopamine
Phase 2Small molecule
A-dopamine is one of 4 small molecule programs targeting Parkinson. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Parkinson
#DrugCompanyPhaseTrials
1Pletal
OtsukaPhase 2
ONO-2808
Ono Pharmaceutical Co. LtdPhase 3
Standard Treatment
Boehringer IngelheimPhase 2
A-dopamine
UUniversity Hospital, Lille
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for A-dopamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Lille